Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
14.39
-0.32 (-2.18%)
Aug 10, 2026, 9:55 AM EDT - Market open
Lyell Immunopharma Revenue
Lyell Immunopharma had revenue of $4.00K in the quarter ending June 30, 2026, a decrease of -50.00%. This brings the company's revenue in the last twelve months to $27.00K, down -55.00% year-over-year. In the year 2025, Lyell Immunopharma had annual revenue of $36.00K, down -40.98%.
Revenue (ttm)
$27.00K
Revenue Growth
-55.00%
P/S Ratio
13,350.76
Revenue / Employee
$168
Employees
161
Market Cap
352.63M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.00K | -25.00K | -40.98% |
| Dec 31, 2024 | 61.00K | -69.00K | -53.08% |
| Dec 31, 2023 | 130.00K | -84.55M | -99.85% |
| Dec 31, 2022 | 84.68M | 74.03M | 695.15% |
| Dec 31, 2021 | 10.65M | 2.89M | 37.31% |
| Dec 31, 2020 | 7.76M | 7.10M | 1,080.52% |
| Dec 31, 2019 | 657.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Clinuvel Pharmaceuticals | 64.24M |
| Foghorn Therapeutics | 36.74M |
| Upstream Bio | 3.32M |
| Compass Therapeutics | 850.00K |
| Vicore Pharma Holding AB | 370.61K |
| SAB Biotherapeutics | 114.70K |
LYEL News
- 3 days ago - Lyell Immunopharma reports Q2 net loss ($44.8M) vs. ($42.7M) last year - TheFly
- 4 days ago - Lyell Immunopharma Quarterly report: Q2 2026 - Filings
- 4 days ago - Lyell Immunopharma Earnings release: Q2 2026 - Filings
- 4 days ago - Lyell Immunopharma Slides: Company presentation - Filings
- 4 days ago - Lyell Immunopharma initiated with a Buy at Stifel - TheFly
- 19 days ago - Lyell Immunopharma initiated with a Buy at B. Riley - TheFly
- 27 days ago - Lyell Immunopharma files to sell 1.1M shares of common stock for holders - TheFly
- 4 weeks ago - Lyell Immunopharma Registration statement: Registration filing - Filings